Grifols has dosed the first patients in two separate Phase III trials designed to support the US label expansion of its immunoglobulin therapies, Gamunex-C and Xembify.

The post First patients dosed in Grifols Phase III immunoglobulin trials appeared first on Clinical Trials Arena.